Burke Group

Home Research Bryostatin 1 Didemniserinolipid B Dictyostatin Halichondrin B Kendomycin Phorboxazole B Spicamycin Trilobin & Trilobacin Thromboxane B2 Group Members Publications Photo Gallery Links

Kendomycin Kendomycin was first isolated in 1996 from Streptomyces violaceoruber. It was found to possess potent activity as both an endothelin receptor antagonist and antisteoporotic agent. It also shows significant antibacterial activity against multiresistant bacteria and a high cytotoxicity against many human tumor cell lines with a GI50 < 0.1µM. Kendomycins interesting biological activity as well as its unique structure has lead to several efforts at total synthesis, the first being completed in 2004.